A joint assessment is a structured information for rapid or full/comprehensive HTAs which is the output of joint production in which 2 or more countries and/or organisations work together to prepare shared products or agreed outcomes (Based on definitions from the HTA Network Strategy (page 24) and the EUnetHTA Recommendations (page 6, footnote 8))

As of March 2016, EUnetHTA has finalised 20 joint assessments: 2 joint assessments during EUnetHTA Project (2006-2008), 3 joint assessments during EUnetHTA JA (2010-2012) and 15 joint assessments during EUnetHTA JA2 (2012-2015).

EUnetHTA JA3 (2016-2020)

Overview Table of Ongoing and Published Assessments

JA3 Rapid Relative Effectiveness Assessment (REA) of pharmaceutical technologies

Ongoing Joint Assessments

Midostaurin with standard chemotherapy in FLT3 positive Acute Myeloid Leukaemia

Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

JA3 Rapid Relative Effectiveness Assessment (REA) of other technologies

Ongoing Collaborative Assessments

Screening of fetal aneuplodies whereby non-invasive prenatal test (NIPT)

Published Collaborative Assessments

Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk

Repetitive transcranial magnetic stimulation for treatment-resistant major depression

Antibacterial-coated Sutures Versus Non-Antibacterial-Coated Sutures for the Prevention of Abdominal, Superficial and Deep Incisional, Surgical Site Infection (SSI)

 

EUnetHTA JA2 (2012-2015)

JA2 Full/Comprehensive assessments 

Fecal Immunochemical Test (FIT) versus guaiac-based fecal occult blood test (FOBT for colorectal cancer screening. (Core HTA 1)

Use of Intravenous immunoglobulins for Alzeheimer's disease including Mild Cognitive Impairment. (Core HTA 2)

Structured telephone support (STS) for adult patients with chronic heart failure. (Core HTA 3)


JA2 Rapid Relative Effectiveness Assessment (REA) of Pharmaceuticals

Canagliflozin for the treatment of type 2 Diabetes Mellitus

Sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) Thyroid Carcinoma, refractory to radioactive Iodine

 Rapid Relative effectiveness Assessment of new Pharmaceuticals for the treatment of Chronic Hepatitis C

Ramucirumab in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction Adenocarcinoma

Vorapaxar for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI)

Zostavax for the prevention of Herpes Zoster and postherpetic Neuralgia


JA2 Rapid Relative Effectiveness Assessment (REA) of other Technologies

Balloon Eustachian tuboplasty for the treatment of Eustachian tube dysfunction

Biodegradable stents for the treatment of refractory or recurrent benign Oesophageal Stenosis

Duodenal-jejunal bypass sleeve for the treatment of Obesity with or without type ii Diabetes Mellitus

Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke

Renal denervation systems for treatment-resistant hypertension

Transcatheter implantable Devices for mitral valve repair in adults with Chronic Mitral Valve Regurgitation

EUnetHTA  JA1 (2010 - 2012)

WP5 JA1 Pilot Pazopanib Report+Appendix

Abdominal Aorta Aneurysm Screening (AAA)

 Prognostic tests for breast cancer recurrence (PTBCR)

EUnetHTA Project (2006 - 2008)

Core HTA on MSCT Angiography

Core HTA on Drug Eluting Stents